Updated Jul 16, 2026 · Last SEC filing 2026-07-13
MoonLake Immunotherapeutics (MLTX) has filed 11 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-13. 6 Form 8-K material event filings were reported by MLTX in the last 90 days. 3 Form 144 notices of proposed sale were filed for MLTX stock. InsiderAlpha tracks every MLTX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001821586 |
| Form 4 filings (90d) | 11 |
|---|---|
| Form 8-K filings (90d) | 6 |
| Form 144 notices (90d) | 3 |
| Latest Form 4 filing | 2026-07-13 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer | S — Open-market sale [10b5-1] | 68.3K | $20.02 | $1.37M | SEC | |
| Santos da Silva Jorge | Chief Executive Officer | S — Open-market sale [10b5-1] | 33.9K | $20.01 | $679K | SEC | |
| Santos da Silva Jorge | Chief Executive Officer | S — Open-market sale | 47.8K | $20.03 | $957K | SEC | |
| Bodenstedt Matthias | Chief Financial Officer | S — Open-market sale | 39.1K | $22.04 | $862K | SEC | |
| Bodenstedt Matthias | Chief Financial Officer | S — Open-market sale | 2.8K | $19.60 | $55K | SEC | |
| Reich Kristian | Chief Scientific Officer | S — Open-market sale | 50.0K | $19.43 | $972K | SEC | |
| Bodenstedt Matthias | Chief Financial Officer | S — Open-market sale | 15.1K | $19.68 | $297K | SEC | |
| Reich Kristian | Chief Scientific Officer | S — Open-market sale | 50.0K | $18.70 | $935K | SEC | |
| Reich Kristian | Chief Scientific Officer | S — Open-market sale | 50.0K | $18.89 | $944K | SEC | |
| Bodenstedt Matthias | Chief Financial Officer | S — Open-market sale | 13.7K | $20.02 | $273K | SEC | |
| Bodenstedt Matthias | Chief Financial Officer | S — Open-market sale | 2.4K | $19.56 | $47K | SEC | |
| Santos da Silva Jorge | Chief Executive Officer | S — Open-market sale | 51.9K | $18.23 | $946K | SEC | |
| Bodenstedt Matthias | Chief Financial Officer | S — Open-market sale [10b5-1] | 1.9K | $19.51 | $38K | SEC | |
| Santos da Silva Jorge | Chief Executive Officer | S — Open-market sale | 98.1K | $18.41 | $1.81M | SEC | |
| Bodenstedt Matthias | Chief Financial Officer | S — Open-market sale [10b5-1] | 85.9K | $18.94 | $1.63M | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for MoonLake Immunotherapeutics (MLTX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Bodenstedt Matthias | 4 | $1.49M |
| Santos da Silva Jorge | 3 | $3.00M |
| Reich Kristian | 3 | $2.85M |
| Loy Spike | 1 | — |
| BVF PARTNERS L P/IL | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in MLTX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live MLTX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.